HTG2014-Section-Header-publications

Publications

Explore HTG publications
with our new search tool. Launch Now

Categories

Reset Categories

Filter by Topics

AACR2023 ADCC Gene Alteration adolescents ALK Angiogenesis Apoptosis Autocrine Signaling B-accute lyphoblastic seukemia B-ALL Biology of neoplasia Biomarkers Bladder Cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN Blood bone Brain Breast Cancer CAR T cell therapy Cardiovascular Disease CDKN2A mutation Cell Free Plasma Cells Chemokines Circulating miRNAs clinical trial Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug sensitivity Efficacy EHE cancer EMT Epstein-Barr ERBB3 Esophageal Cancer estrogen and progesteron receptors Exosomes extracellular miRNAs Extracellular Vesicles Feasibility FFPE FGF Ligand Trap FGFR Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER-2 HER2- HLA-E Homing HPV HR+ HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Cells Immune Checkpoint Inhibitors Immune Response Immune System Immuno-Oncology Immunotherapy Integrins IOA- 244 IRP Kidney LAG3+ Liposarcoma Liquid Biopsy Liver liver liver tissue Lung lungs Lupus Lymphocytes Lymphoma lymphoma Melanoma melanoma Mesothelioma Microenvironment miRNA miRNA WTA Molecular Characterization Mouse mRNA custom mTOR signaling Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets OBP Oral cancer Oral Cancer oral squamous cell carcinoma OSCC Osteoarthritis palbociclib PALLET PALOMA PALOMA-2 PanB Pancreas Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-L1 PDX model PENELOPE-B PFAS PI3K inhibitors PIK3CA mutation PIP Plasma Platform Comparison Programmed cell death protein 1 Prostate Prostate Cancer qNPA qPCR Rbsig Renal Cell Carcinoma Reproductive Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Squamous cell carcinoma STAT6 pathway Sub-typing Testicular cancer Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Triple Negative Breast CancerTNBC Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue
Reset Filter Reset All

2019

Sarcoidosis and Coccidioidomycosis Share Common Tissue Transcriptome Expression Profiles

Casanova, N. G., et al.  Sarcoidosis and Coccidioidomycosis Share Common Tissue Transcriptome Expression Profiles. American Journal of Respiratory and Critical Care Medicine 2019;199:A3079

View External Link

Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial

Sinn, B.V., et al. Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial. Abstract PD5-05 presented at: American Association for Cancer Research Breast Symposium; December 4-8, 2019. San Antonio, Texas.

View External Link

Target Capture RNA Sequencing as a Method of Predicting Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer a Multi-institutional Study

Kanji, Z. S., et al. Target Capture RNA Sequencing as a Method of Predicting Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer a Multi-institutional Study. Journal of the International Hepato-Pancreato-Biliary Association. 2019; 21(S1):S14-S15.

View External Link

Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict the efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Battaglin, F., et al. Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict the efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.  American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19, 2019, San Francisco, CA.

View External Link

2018

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Younes, A., et al. A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Blood 2019 (132) S1: 784-784. https://doi.org/10.1182/blood-2018-99-112988

View External Link

Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations

Luke J., et al. Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations. Poster session presented at: ESMO 2018 Congress. Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

View External Link

A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC)patients

Sunakawa, Y. et al. A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC)patients. Abstract presented at: 2018 Congress European Society for Medical Oncology (ESMO); 2018 Oct 21; Munich, Germany. Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281.

View External Link

Detection of a MicroRNA molecular signature of ultraviolet radiation in the superficial regions of melanocytic nevi on sun-exposed skin

Bell, A. et al, Detection of a MicroRNA molecular signature of ultraviolet radiation in the superficial regions of melanocytic nevi on sun-exposed skin. Modern Pathology 2018 Jun 28. doi: 10.1038/s41379-018-0088-5. [Epub ahead of print].

Download pdf 18.9MB
View External Link

Page last updated May 22, 2023